Targeting of G-Quadruplex Harboring Pre-miRNA 92b by LNA Rescues PTEN Expression in NSCL Cancer Cells

被引:34
作者
Arachchilage, Gayan Mirihana [1 ,2 ]
Kharel, Prakash [1 ]
Reid, Joshua [1 ]
Basu, Soumitra [1 ]
机构
[1] Kent State Univ, Dept Chem & Biochem, Kent, OH 44242 USA
[2] Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA
基金
美国国家卫生研究院;
关键词
ANTISENSE OLIGONUCLEOTIDES; MICRORNA BIOGENESIS; HUMAN-DISEASE; SMALL RNAS; THERAPEUTICS; CHALLENGES; GENOMICS; STABILIZATION; MATURATION; INHIBITORS;
D O I
10.1021/acschembio.7b00749
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since the elevated levels of microRNAs (miRNAs) often cause various diseases, selective inhibition of miRNA maturation is an important therapeutic strategy. Commonly used anti-miRNA strategies are limited to targeting of mature miRNAs, as the upstream targeting of miRNA maturation with an oligonucleotide is challenging due to the presence of a stable pre-miRNA stem-loop structure. Previously, we reported that about 16% of known human pre-miRNAs have the potential to adopt G-quadruplex (GQ) structures alternatively to canonical stem-loops. Herein, we showed that a rationally designed locked nucleic acid (LNA) binds specifically the GQ conformation of pre-miRNA 92b and inhibits pre-miRNA maturation. Further, we showed that the LNA treatment rescues PTEN expression in non-small-cell lung cancer (NSCLC) cells, which is suppressed by the elevated level of miRNA 92b. Treatment of LNA significantly decreases the IC50 of doxorubicin for NSCLC cells. This strategy can be developed as a novel anti-miRNA therapeutic approach to target GQ harboring miRNAs. This can potentially be a more powerful approach than targeting of the mature miRNA, as it is an upstream targeting and can reduce both 3' and the 5' mature miRNA levels at once.
引用
收藏
页码:909 / 914
页数:6
相关论文
共 33 条
[1]   A Potassium Ion-Dependent RNA Structural Switch Regulates Human Pre-miRNA 92b Maturation [J].
Arachchilage, Gayan Mirihana ;
Dassanayake, Arosha C. ;
Basu, Soumitra .
CHEMISTRY & BIOLOGY, 2015, 22 (02) :262-272
[2]  
Avitabile Concetta, 2012, Artif DNA PNA XNA, V3, P88, DOI 10.4161/adna.20911
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]   MicroRNA therapeutics [J].
Broderick, J. A. ;
Zamore, P. D. .
GENE THERAPY, 2011, 18 (12) :1104-1110
[5]  
Casalini P, 2009, J BUON, V14, pS17
[6]  
Dias N, 2002, MOL CANCER THER, V1, P347
[7]   MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells [J].
Ebert, Margaret S. ;
Neilson, Joel R. ;
Sharp, Phillip A. .
NATURE METHODS, 2007, 4 (09) :721-726
[8]   MicroRNAs in lung diseases: Recent findings and their pathophysiological implications [J].
Ebrahimi, Ammar ;
Sadroddiny, Esmaeil .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 34 :55-63
[9]   LNA-mediated microRNA silencing in non-human primates [J].
Elmen, Joacim ;
Lindow, Morten ;
Schutz, Sylvia ;
Lawrence, Matthew ;
Petri, Andreas ;
Obad, Susanna ;
Lindholm, Marie ;
Hedtjarn, Maj ;
Hansen, Henrik Frydenlund ;
Berger, Urs ;
Gullans, Steven ;
Kearney, Phil ;
Sarnow, Peter ;
Straarup, Ellen Marie ;
Kauppinen, Sakari .
NATURE, 2008, 452 (7189) :896-U10
[10]   Most mammalian mRNAs are conserved targets of microRNAs [J].
Friedman, Robin C. ;
Farh, Kyle Kai-How ;
Burge, Christopher B. ;
Bartel, David P. .
GENOME RESEARCH, 2009, 19 (01) :92-105